A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand

被引：0

作者：

Bhardwaj, Nina ^{[1
]}

Friedlander, Philip ^{[2
]}

Pavlick, Anna ^{[3
]}

Ernstoff, Marc ^{[4
]}

Gastman, Brian ^{[5
]}

Hanks, Brent ^{[6
]}

Albertini, Mark ^{[7
]}

Luke, Jason ^{[8
]}

Yellin, Michael ^{[9
]}

Keler, Tibor ^{[9
]}

Davis, Thomas ^{[9
]}

Vitale, Laura ^{[9
]}

Blazquez, Ana ^{[10
]}

Morishima, Chihiro ^{[11
]}

Danaher, Patrick ^{[12
]}

Warren, Sarah ^{[12
]}

Salim, Bob ^{[13
]}

Hess, Bruce ^{[11
]}

D'Amico, Leonard ^{[11
]}

Lundgren, Lisa ^{[14
]}

Disis, Nora ^{[11
]}

Cheever, Martin ^{[14
]}

Fling, Steven ^{[14
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Mt Sinai Beth Israel, New York, NY USA

[3] NYU Lagone Med Ctr, New York, NY USA

[4] Roswell Pk Canc Inst, Buffalo, NY USA

[5] Cleveland Clin, Cleveland, OH 44106 USA

[6] Duke, Durham, NC USA

[7] Univ Wisconsin, Madison, WI USA

[8] Univ Chicago Med, Chicago, IL USA

[9] Celldex Therapeut, Needham, MA USA

[10] Mt Sinai, New York, NY USA

[11] Univ Washington, Seattle, WA 98195 USA

[12] Nanostring Technol, Seattle, WA USA

[13] Axio Res, Seattle, WA USA

[14] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 43 条

[21] Generated SecPen＿NY-ESO-1＿ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses
Yunkai Yang
Xiaohan Guo
Bo Hu
Peng He
Xiaowu Jiang
Zuohuan Wang
Huaxing Zhu
Lina Hu
Minghua Yu
Meiqing Feng
Acta Pharmaceutica Sinica B, 2021, 11 (02) : 476 - 487
[22] Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses
Yang, Yunkai
Guo, Xiaohan
Hu, Bo
He, Peng
Jiang, Xiaowu
Wang, Zuohuan
Zhu, Huaxing
Hu, Lina
Yu, Minghua
Feng, Meiqing
ACTA PHARMACEUTICA SINICA B, 2021, 11 (02) : 476 - 487
[23] A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Krishnadas, Deepa K.
Shusterman, Suzanne
Bai, Fanqi
Diller, Lisa
Sullivan, Janice E.
Cheerva, Alexandra C.
George, Rani E.
Lucas, Kenneth G.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (10) : 1251 - 1260
[24] A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Deepa K. Krishnadas
Suzanne Shusterman
Fanqi Bai
Lisa Diller
Janice E. Sullivan
Alexandra C. Cheerva
Rani E. George
Kenneth G. Lucas
Cancer Immunology, Immunotherapy, 2015, 64 : 1251 - 1260
[25] Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
Pavlick, Anna
Blazquez, Ana B.
Meseck, Marcia
Lattanzi, Michael
Ott, Patrick A.
Marron, Thomas U.
Holman, Rose Marie
Mandeli, John
Salazar, Andres M.
McClain, Christopher B.
Gimenez, Gustavo
Balan, Sreekumar
Gnjatic, Sacha
Sabado, Rachel Lubong
Bhardwaj, Nina
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (01) : 70 - 80
[26] Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Yuan, Jianda
Adamow, Matthew
Ginsberg, Brian A.
Rasalan, Teresa S.
Ritter, Erika
Gallardo, Humilidad F.
Xu, Yinyan
Pogoriler, Evelina
Terzulli, Stephanie L.
Kuk, Deborah
Panageas, Katherine S.
Ritter, Gerd
Sznol, Mario
Halaban, Ruth
Jungbluth, Achim A.
Allison, James P.
Old, Lloyd J.
Wolchok, Jedd D.
Gnjatic, Sacha
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (40) : 16723 - 16728
[27] First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient
Pollack, Seth M.
Lu, Hailing
Gnjatic, Sacha
Somaiah, Neeta
O'Malley, Ryan B.
Jones, Robin L.
Hsu, Frank J.
ter Meulen, Jan
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 302 - 306
[28] Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
Jung, Eun Hee
Jang, Hee Ryeong
Kim, Se Hyun
Suh, Koung Jin
Kim, Yu Jung
Lee, Ju-Hyun
Chung, Jin-Haeng
Kim, Miso
Keam, Bhumsuk
Kim, Tae Min
Kim, Dong-Wan
Heo, Dae Seog
Lee, Jong Seok
THORACIC CANCER, 2021, 12 (05) : 619 - 630
[29] Flt3 ligand augments immune responses to soluble PD1-based DNA vaccine via expansion of type 1 conventional DCs
Cai, Zongyu
Qiao, Yaru
Wuri, Qimuge
Zhang, Ke
Qu, Xueli
Zhang, Shiqi
Wu, Hui
Wu, Jiaxin
Wang, Chu
Yu, Xianghui
Kong, Wei
Zhang, Haihong
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 141
[30] Cytotoxic T Lymphocyte-associated Antigen 4 Blockade Enhances Polyfunctional NY-ESO-1 Specific T Cell Responses in Metastatic Melanoma Patients With Tumor Regression
Yuan, Jianda
Gnjatic, Sacha
Li, Hao
Powel, Sarah
Gallardo, Humilidad
Ritter, Erika
Rasalan, Teresa S.
Manukian, Gregor
Xu, Yinyan
Terzulli, Stephanie
Ritter, Gerd
Old, Lloyd
Allison, James P.
Wolchok, Jedd D.
JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 934 - 935

← 1 2 3 4 5 →